Abstract
Once-weekly lonapegsomatropin (TransCon hGH) is an investigational prodrug of somatropin in development for treatment of growth hormone deficiency (GHD). Lonapegsomatropin demonstrated efficacy and safety in both treatment-naïve and treatment-experienced children in the 52-week heiGHt Trial and 26-week fliGHt Trial, respectively.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
